Exenatide long-acting - AstraZeneca

Drug Profile

Exenatide long-acting - AstraZeneca

Alternative Names: Bydureon; BYDUREON BCise; Bydureon Pen; Byetta LAR; Exenatide extended-release for injectable suspension; Exenatide LAR; Exenatide once-weekly suspension; Ready to Use Exenatide Once Weekly

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amylin Pharmaceuticals
  • Developer AstraZeneca; Eli Lilly; Hongkong Sansheng; University Medical Center Hamburg-Eppendorf
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Obesity

Most Recent Events

  • 29 Jun 2018 Committee for Medicinal Products for Human Use (CHMP) recommends approval of exenatide long-acting (BYDUREON® BCise™) for the treatment of Type-2 diabetes mellitus
  • 04 Apr 2018 Launched for Type-2 diabetes mellitus (Adjunctive treatment) in USA (SC)
  • 03 Apr 2018 Registered for Type-2 diabetes mellitus (Adjunctive treatment) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top